דוסיטקסל טבע ® 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון
abic marketing ltd - docetaxel 27.73 mg / 1 ml - concentrate and solvent for solution for infusion - docetaxel - breast cancerdocetaxel teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have inclu
דוסטקסל ג'נמדיקס
genmedix - docetaxel 20 mg/ml - concentrate for solution for infusion - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracyclin
דוסיטקסל טבע ® תמיסה מרוכזת בבקבוקון יחיד
abic marketing ltd - docetaxel 20 mg/ml - concentrate for solution for infusion - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline
קפציטבין טבע 150 מג
abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 150 mg - capecitabine
קפציטבין טבע 500 מג
abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine
נרלינקס
medison pharma ltd - neratinib as maleate - טבליה - neratinib as maleate 40 mg - neratinib
טוקייסה 150 מג
merck sharp & dohme (israel-1996) ltd - tucatinib - טבליות מצופות פילם - tucatinib 150 mg - tucatinib
טוקייסה 50 מג
merck sharp & dohme (israel-1996) ltd - tucatinib - טבליות מצופות פילם - tucatinib 50 mg - tucatinib